cifostodine: INN; was 2',3'-cyclic CMP 1979-93; CYTIDINE CYCLIC-2',3'-MONOPHOSPHATE was see CYTIDINE CYCLIC MONOPHOSPHATE 1980-93; use CYCLIC CMP to search 1980-93 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 68934 |
| CHEMBL ID | 2104086 |
| CHEBI ID | 27652 |
| SCHEMBL ID | 1229741 |
| MeSH ID | M0071682 |
| Synonym |
|---|
| citidine cyclic 2',3'-(hydrogen phosphate) |
| 633-90-9 |
| cifostodinum |
| cytidine 2',3'-(hydrogen phosphate) |
| CHEBI:27652 , |
| cifostodina |
| C02354 |
| cifostodine |
| 1-[(3ar,4r,6r,6ar)-2-hydroxy-6-(hydroxymethyl)-2-oxo-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3,2]dioxaphosphol-4-yl]-4-aminopyrimidin-2-one |
| cifostodine [inn] |
| 1-(4-amino-1,2-dihydro-2-oxo-1-pyrimidinyl)ribofuransoe-2,3-cyclo(hydrogenphosphat) |
| unii-74b4vjv0wv |
| cytidine cyclic 2',3'-(hydrogen phosphate) |
| 2',3'-ccmp |
| cifostodinum [latin] |
| einecs 211-198-5 |
| cifostodina [spanish] |
| 74b4vjv0wv , |
| CHEMBL2104086 |
| SCHEMBL1229741 |
| DTXSID90212690 |
| cytidine-2'(&3')-monophosphate |
| cytidine2,3-(hydrogenphosphate) |
| Q27103243 |
| Role | Description |
|---|---|
| Escherichia coli metabolite | Any bacterial metabolite produced during a metabolic reaction in Escherichia coli. |
| mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
| Mycoplasma genitalium metabolite | Any bacterial metabolite produced during a metabolic reaction in Mycoplasma genitalium. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| 2',3'-cyclic pyrimidine nucleotide | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.11) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||